Earlier research has evidenced that RUNX1 exerts the opposite effect in BC3: it acts as a tumor inhibitor in ER‐positive (ER+) BC and is carcinogenic in ER‐negative (ER‐) BC (Figure S2A). The gene discussed is RUNX1; the disease is breast cancer.